Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series.

Dal Pino, Beatrice; Bigazzi, Federico; Sbrana, Francesco

Monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (mAb PCSK9i) could be administered to lower LDL cholesterol in patients with muscle-related adverse events, but intolerance to mAb PCSK9i has also been described [[2]]. In Familial Hypercholesterolemia (FH), statins treatment is the first choice to lower LDL cholesterol and to reduce cardiovascular morbidity and mortality, however, up to 10% of patients treated with statins report intolerance [[1]]. We enrolled 5 patients in chronic LA (mean age 64 ± 8 years, female 60%) affected by heterozygous FH and AtheroSclerotic CardioVascular Disease (ASCVD), with history of statin intolerance and mAb PCSK9i adverse events (flue like syndrome in 3/5 patients, severe CPK increase in 1/5 patient and low therapeutic compliance in 1/5 patient).

STATINS (Cardiovascular agents); DYSLIPIDEMIA; PATIENT compliance

Therapeutic Apheresis & Dialysis, 2023, Vol 27, Issue 5, p978

1744-9979

Academic Journal

10.1111/1744-9987.14025